{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:43:23Z","timestamp":1789469003658,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000262","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002089","name":"Fight for Sight Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001116","name":"Foundation Fighting Blindness Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031367","name":"Choroideremia Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xops.2026.101316","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:34:50Z","timestamp":1783352090000},"page":"101316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quantification of Ocular Gene Therapy\u2013Related Inflammation Using the VRMACS Grading System"],"prefix":"10.1016","volume":"6","author":[{"given":"Maram E.A.","family":"Abdalla Elsayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2825-8399","authenticated-orcid":false,"given":"Robert E.","family":"MacLaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101316_bib1","article-title":"Luxturna (voretigene neparvovec-rzyl): regulatory approval details and approval history","year":"2017","journal-title":"FDA"},{"issue":"10436","key":"10.1016\/j.xops.2026.101316_bib2","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.xops.2026.101316_bib3","first-page":"1152","article-title":"Suprachoroidal delivery of RGX-314 for diabetic retinopathy: the phase II ALTITUDE study","volume":"63","author":"Dhoot","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101316_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2025.101354","article-title":"Gene therapy\u2013associated uveitis (GTAU): understanding and mitigating the adverse immune response in retinal gene therapy","volume":"106","author":"Purdy","year":"2025","journal-title":"Prog Retin Eye Res"},{"issue":"10097","key":"10.1016\/j.xops.2026.101316_bib5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomized, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.xops.2026.101316_bib6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation\u2013associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1016\/j.xops.2026.101316_bib7","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.xops.2026.101316_bib8","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ophtha.2024.02.023","article-title":"Assessment of visual function with cotoretigene toliparvovec in X-linked retinitis pigmentosa: the randomized XIRIUS phase 2\/3 study","volume":"131","author":"Lam","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101316_bib9","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3389\/fphar.2019.01076","article-title":"Outcome measures used in ocular gene therapy trials: a scoping review of current practice","volume":"10","author":"Jolly","year":"2019","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.xops.2026.101316_bib10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ymthe.2020.11.029","article-title":"Treating RPE65-associated retinal dystrophy: clinical perspective","volume":"29","author":"Maguire","year":"2021","journal-title":"Mol Ther"},{"issue":"9923","key":"10.1016\/j.xops.2026.101316_bib11","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2026.101316_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","article-title":"Choroideremia gene therapy phase 2 clinical trial: 24-month results","volume":"197","author":"Lam","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.xops.2026.101316_bib13","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","article-title":"Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial","volume":"137","author":"Fischer","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"09","key":"10.1016\/j.xops.2026.101316_bib14","article-title":"Gene therapy for choroideremia using an adeno-associated viral vector encoding Rab escort protein 1: the REGENERATE open-label trial","volume":"11","author":"Cehajic-Kapetanovic","year":"2024","journal-title":"NIHR EME Programme"},{"issue":"10","key":"10.1016\/j.xops.2026.101316_bib15","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1038\/s41591-023-02520-3","article-title":"Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial","volume":"29","author":"MacLaren","year":"2023","journal-title":"Nat Med"},{"issue":"10045","key":"10.1016\/j.xops.2026.101316_bib16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(16)30783-8","article-title":"Benefits of gene therapy for both eyes","volume":"388","author":"MacLaren","year":"2016","journal-title":"Lancet"},{"issue":"15-16","key":"10.1016\/j.xops.2026.101316_bib17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1089\/hum.2024.017","article-title":"Safety of bilateral, sequential retinal gene therapy in choroideremia: the GEMINI study","volume":"35","author":"MacLaren","year":"2024","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1016\/j.xops.2026.101316_bib18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"First-in-human gene therapy trial for X-linked retinitis pigmentosa caused by RPGR mutations","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.xops.2026.101316_bib19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/genes12040601","article-title":"Accurate quantification of AAV vector genomes by quantitative PCR","volume":"12","author":"Martinez-Fernandez de la Camara","year":"2021","journal-title":"Genes (Basel)"},{"issue":"3","key":"10.1016\/j.xops.2026.101316_bib20","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ymthe.2025.01.028","article-title":"Characterization of the ocular inflammatory response to AAV reveals divergence by sex and age","volume":"33","author":"Clare","year":"2025","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.xops.2026.101316_bib21","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: phase I\/IIa intravitreal trial","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.xops.2026.101316_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/jamaophthalmol.2024.5375","article-title":"Five-year outcomes of lenadogene nolparvovec gene therapy in Leber hereditary optic neuropathy","volume":"143","author":"Yu-Wai-Man","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.xops.2026.101316_bib23","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ymthe.2025.01.028","article-title":"Ocular inflammatory responses to AAV vary by sex and age","volume":"33","author":"Clare","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.xops.2026.101316_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101273","article-title":"Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies","volume":"32","author":"Chhabra","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10","key":"10.1016\/j.xops.2026.101316_bib26","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41591-018-0185-5","article-title":"Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia","volume":"24","author":"Xue","year":"2018","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.xops.2026.101316_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/tvst.12.5.21","article-title":"Microperimetry reliability assessed from fixation performance","volume":"12","author":"Josan","year":"2023","journal-title":"Transl Vis Sci Technol"},{"issue":"3","key":"10.1016\/j.xops.2026.101316_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/aos.16780","article-title":"Test-retest variability of mesopic microperimetry parameters in retinitis pigmentosa","volume":"103","author":"Karuntu","year":"2025","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.xops.2026.101316_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/tvst.10.2.28","article-title":"Low-luminance visual acuity deficit in choroideremia and RPGR-associated retinitis pigmentosa","volume":"10","author":"Wood","year":"2021","journal-title":"Transl Vis Sci Technol"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266691452600254X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266691452600254X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:22:04Z","timestamp":1789464124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266691452600254X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S266691452600254X"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101316","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of Ocular Gene Therapy\u2013Related Inflammation Using the VRMACS Grading System","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101316"}}